 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C39H64N12O19 |
| Molecular Weight | 1005.0 |
| Exact Mass | 1004.44 |
| CAS # | 106021-96-9 |
| PubChem CID | 123872 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.419g/cm3 |
| Boiling Point | 1682.6ºC at 760mmHg |
| Flash Point | 971.4ºC |
| Vapour Pressure | 0mmHg at 25°C |
| Index of Refraction | 1.573 |
| LogP | -12.6 |
| Hydrogen Bond Donor Count | 17 |
| Hydrogen Bond Acceptor Count | 21 |
| Rotatable Bond Count | 36 |
| Heavy Atom Count | 70 |
| Complexity | 1920 |
| Defined Atom Stereocenter Count | 8 |
| SMILES | CC([C@H](N)C(N[C@@H](C(NCC(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(O)=O)CCCCN)=O)CC(O)=O)=O)CC(N)=O)=O)CO)=O)CCC(O)=O)=O)CCC(O)=O)=O)=O)CCC(N)=O)=O)C |
| InChi Key | NIXBZDOQHRZFDR-OEWCNXHOSA-N |
| InChi Code | InChI=1S/C39H64N12O19/c1-17(2)31(43)38(68)47-18(6-9-25(41)53)32(62)44-15-27(55)45-19(7-10-28(56)57)33(63)46-20(8-11-29(58)59)34(64)51-24(16-52)37(67)49-22(13-26(42)54)35(65)50-23(14-30(60)61)36(66)48-21(39(69)70)5-3-4-12-40/h17-24,31,52H,3-16,40,43H2,1-2H3,(H2,41,53)(H2,42,54)(H,44,62)(H,45,55)(H,46,63)(H,47,68)(H,48,66)(H,49,67)(H,50,65)(H,51,64)(H,56,57)(H,58,59)(H,60,61)(H,69,70)/t18-,19-,20-,21-,22-,23-,24-,31-/m0/s1 |
| Chemical Name | (2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]hexanoic acid |
| Synonyms | IL-1beta (163-171); Interleukin-1beta (163-171) |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Mouse thymocyte proliferation is stimulated by human β-interleukin I (163-171) (12.5-400 μg/mL, 72 hours) [6]. |
| ln Vivo | In a BALB/c mouse model of hypoimmunogenic fibrosarcoma (CE-2), human beta-interleukin I (163-171) administered at a dose of 50 μg per day results in a consistent, albeit restricted, suppression of tumor growth [2]. The initial immunological response to the antigen is enhanced by T-dependent antigen-SRBC in conjunction with human β-interleukin I (163–171) (1 μmole/kg, i.v.) [3]. |
| References |
[1]. In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta. J Immunol. 1987 Aug 1;139(3):800-4. [2]. Ability of a nonapeptide of the human IL-1 beta to recruit anti-tumor reactivity in recipient mice. J Immunol. 1989 Jan 15;142(2):712-8. [3]. In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta. J Exp Med. 1988 Aug 1;168(2):675-86. [4]. (1997). Interleukin 1 and Its Synthetic Peptide 163–171 as Vaccine Adjuvants. Vaccine Design pp 167-173. [5]. Binding and internalization of the 163-171 fragment of human IL-1 beta. Cytokine. 1992 May;4(3):201-4. [6]. Immunomodulating activity of analogs of noninflammatory fragment 163-171 of human interleukin-1beta. Immunopharmacology. 1998 Jan;38(3):237-45. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9950 mL | 4.9751 mL | 9.9502 mL | |
| 5 mM | 0.1990 mL | 0.9950 mL | 1.9900 mL | |
| 10 mM | 0.0995 mL | 0.4975 mL | 0.9950 mL |